On the horizon...Are Merck's and Bayer's just-released Q1 results (with focus on their Animal Health revenue) good indicators of what to expect in BNC's Q3 financial results to be released on May 9?
Don't know... but have been tracking and thought I would share the results these two companies seemed quite/very pleased with...
Merck reported this morn and AH Q1-12 revenue up 8% (vs Q1-11).
Bayerreported yesterday and AH Q1-12 revenue up 7.8% (vs Q1-11)*
*not adjusted for currency...see pages 14 and 15 in link below.
Plus, it is written (in April's Newsletter in the note to Bioniche Shareholders from Mr. McRae):
"We are now well-positioned to deliver on our objectives. We are continuing to supply a formulation of MCC, UrocidinTM, to Endo Pharmaceuticals for use in the ongoing Phase III clinical program. We are also building our core Animal Health franchise and we are seeing positive trends in Animal Health product sales. We are looking to introduce a new canine oncology product and an anti-anxiety product for dogs to the market over the coming months. In addition, our internal review of capital expenditure priorities has led to a reduction in the cash burn rate and we remain committed to a zero cash burn rate in Fiscal 2013."
And, hopefully Bioniche includes an fyi (or more) in the May 9 commentary section about the upcoming presentation at the AUA re Urocidin.
Seems like things are coming together in BNC's AH division. Recall what Bioniche reported last quarter for their AH revenue (quote from the report):
"This has been driven by a 21.3% increase in Animal Health product sales to $7.4 million in Q2, Fiscal 2012 (compared to $6.1 million in Q2, Fiscal 2011) and an increase in the gross margins of Animal Health products to 52.4% in the most recent quarter (compared to 51.4% in Q2, Fiscal 2011).
I look forward to learning more on May 9! rg